Solana has been in a significant pullback over the last few days, with its price currently ranging between $126 and $140, down from recent highs. Despite this, institutional interest in SOL still attracted over $100 million in net inflows in November, pushing the Solana price prediction narratives up to $500. However, while the Solana price […] The post Will Solana Price Ever Hit $500? Analysts Are Keen on Remittix Expected to Outpace SOL Gains Tenfold appeared first on Live Bitcoin News.Solana has been in a significant pullback over the last few days, with its price currently ranging between $126 and $140, down from recent highs. Despite this, institutional interest in SOL still attracted over $100 million in net inflows in November, pushing the Solana price prediction narratives up to $500. However, while the Solana price […] The post Will Solana Price Ever Hit $500? Analysts Are Keen on Remittix Expected to Outpace SOL Gains Tenfold appeared first on Live Bitcoin News.

Will Solana Price Ever Hit $500? Analysts Are Keen on Remittix Expected to Outpace SOL Gains Tenfold

2025/12/05 18:54
4 min read

Solana has been in a significant pullback over the last few days, with its price currently ranging between $126 and $140, down from recent highs. Despite this, institutional interest in SOL still attracted over $100 million in net inflows in November, pushing the Solana price prediction narratives up to $500.

However, while the Solana price prediction of reaching $500 is highly speculative and depends on major technical and regulatory breakthroughs, a new contender, Remittix (RTX), is capturing investor attention by offering a utility-driven path to growth that could eclipse SOL’s projected percentage gains.

Solana Price Prediction Faces a Technical Roadblock

The trending Solana price prediction of $500 is currently dividing the market as top analysts weigh in on the coin’s future. According to analysts from MEXC, XS.com, and others, the journey looks tough and clouded by technical challenges. A critical point for many analysts is that the SOL price needs first to reclaim its $140 zone to stabilise its current downtrend.

Interest in the Solana price prediction of $500 varies widely across the market, as opposing opinions continue to surface with every drawdown. One analysis from MEXC suggests a moderate scenario where SOL could test the $400-$500 range in 2026-2027.

A more aggressive Solana price prediction from XS.com targets $420 in 2026 and $550 in 2027, contingent on successful AI integration and network upgrades such as Firedancer. Achieving these lofty targets requires not only overcoming significant technical resistance around $180-$188 but also favourable macro conditions.

Why Remittix is Positioned for Exponential Growth

In stark contrast to Solana’s dependence on market sentiment and technical breakouts, Remittix is building momentum through tangible product development and real-world utility. The project’s live iOS wallet is available on the App Store, with a significant platform update scheduled for December 2025 to activate its core crypto-to-fiat transfer capabilities.

The project’s ongoing new user onboarding, having raised over $28.4 million, demonstrates strong market confidence in its PayFi model, which directly targets the $860 billion remittance industry. Unlike speculative assets, Remittix’s value proposition is grounded in providing a practical, scalable payments infrastructure, verified by CertiK’s Grade A audit.

Comparing The Solana vs Remittix Project

FeatureSolanaRemittix
Current Price & Trend~$130.69; in a significant downtrend, battling key support$0.119; gaining fast recognition as a Low-cap PayFi asset with strong utility
Primary Use CaseHigh-throughput innovative contract platform for DeFi, NFTsPayFi / Direct crypto-to-bank transfers
Key Growth DriverTechnical breakouts, ETF approvals, and successful network upgradesLive product roadmap, real-world adoption, CEX listings
Market SentimentCautious; institutional inflows persist despite price weaknessBullish; driven by real product success and imminent utility

Conclusion

Solana’s potential to reach $500 is a high-risk, long-term bet contingent on a perfect alignment of technical recovery, bullish market cycles, and regulatory wins. For investors seeking assets with clearer, near-term catalysts and exponential growth potential, Remittix presents a compelling alternative.

Its focus on a live product, a verified development schedule, and direct application in the massive global payments sector positions it for gains that could outpace even the most optimistic SOL projections.

Discover the future of PayFi with Remittix by checking out their project here:

Website: https://remittix.io/

Socials: https://linktr.ee/remittix

$250,000 Giveaway: https://gleam.io/competitions/nz84L-250000-remittix-giveaway

Frequently Asked Questions:

  1. Why is Remittix attracting investor interest over Solana? Remittix offers a utility-driven model with a live product and scheduled updates, providing tangible growth catalysts. In contrast, SOL’s near-term price is mired in technical weakness and speculative sentiment.
  2. Which asset has higher growth potential? While SOL is a large-cap asset with significant volatility, utility-driven projects like Remittix, with lower market caps and imminent product launches, are positioned for greater percentage gains driven by adoption.

Disclaimer: This is a paid post and should not be treated as news/advice. LiveBitcoinNews is not responsible for any loss or damage resulting from the content, products, or services referenced in this press release.

The post Will Solana Price Ever Hit $500? Analysts Are Keen on Remittix Expected to Outpace SOL Gains Tenfold appeared first on Live Bitcoin News.

Market Opportunity
Everscale Logo
Everscale Price(EVER)
$0.00448
$0.00448$0.00448
+2.75%
USD
Everscale (EVER) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26